This is a working overview of AOD-9604, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-03-22. Anything still debated is marked as such rather than presented as settled.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
| Property | Value | Notes |
|---|---|---|
| Typical storage temperature | -20 °C | Lyophilized peptide; protect from moisture and light. |
| Typical analytical method | HPLC and mass spectrometry | Used to confirm identity and estimate purity. |
| Common synonyms | AOD9604; hGH 176-191 | Naming varies by supplier and publication. |
| Disulfide bonds | One | Affects folded structure and stability. |
| Typical research purity | ≥95% | Value depends on supplier and analytical method. |
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
SPINA-GR is a calculated biomarker for insulin sensitivity. It represents insulin receptor gain. The method of calculation is based on a time-discrete nonlinear feedback model of insulin-glucose homeostasis that is rooted in the MiMe-NoCoDI modeling platform for endocrine systems.
Heath Hocking (born 27 December 1987) is a former professional Australian rules footballer who played for the Essendon Football Club in the Australian Football League (AFL). Originally from Mooroolbark, he was drafted by Essendon with the 20th selection in the 2006 rookie draft from Eastern Ranges in TAC Cup. He was elevated to the main list in 2007, playing one game late in the 2007 season. Hocking is a solid and hard-at-it midfielder, who primarily plays a defensive tagging role on opposition midfielders. He finished second in the Essendon's best and fairest award, the Crichton Medal, in 2010 and fifth in 2011. His father, Graham Hocking played one game for South Melbourne in 1971 and his older brother Evan has played in the Victorian Football League for Port Melbourne Football Club. Hocking, along with 33 other Essendon players, was found guilty of using a banned performance-enhancing substance, thymosin beta-4, as part of Essendon's sports supplements program during the 2012 season. He and his teammates were initially found not guilty in March 2015 by the AFL Anti-Doping Tribunal, but a guilty verdict was returned in January 2016 after an appeal by the World Anti-Doping Agency. He was suspended for two years which, with backdating, ended in November 2016; as a result, he served approximately fourteen months of his suspension and missed the entire 2016 AFL season.
== Risks == Solid evidence is hard to obtain, as these substances come from many different environments cross-culturally and therefore give variable results, because of variations in growth and extraction. The same is also true for unnatural substances, because variations in consumption and individual sensitivity can affect outcomes. Folk medicine and self-prescribed methods can be potentially harmful, as their adverse effects are not fully known and are therefore not made aware to the people searching this topic on the internet.
== History == Einstein Bros. was created by the chain restaurant corporation Boston Chicken (now Boston Market) in 1995, as a way to market breakfast foods. The chain is now owned by Panera Brands. Boston Chicken, Inc. originally formed the Einstein and Noah Bagel Corporation as Progressive Bagel Concepts, Incorporated (PBCI) in March 1995, when it purchased four retail bagel chains, all located in regions of the United States that did not have longstanding bagel traditions. These companies included Offerdahl's Bagel Gourmet (Fort Lauderdale), Bagel & Bagel (Kansas City), Baltimore Bagel (San Diego), and Brackman Brothers, Incorporated (Salt Lake City). Each found that their stores were similar in that they offered both original and new bagel flavors in wealthy neighborhoods where the customers had relatively little previous exposure to bagels. Noah's Bagels was founded in 1989 by Noah Alper on College Avenue in Berkeley, California. In 1996, the chain of 38 stores was sold to Einstein Bros. for $100 million.
Sources: en.wikipedia.org
== History == In the early 1960s, Dr. Arnold Kadish, a physician working at Loma Linda University, developed a closed-loop device for blood glucose control using a double-lumen autoanalyzer to measure blood glucose linked to an intravenous insulin infusion pump. Although it worked, the prototype was considered so bulky, worn as a backpack, and complicated, that it was never commercialized. In 1976, the first commercialized insulin pump was created and was named the Biostator. The pump was a 60 kg bedside device. It also had the capability of monitoring blood glucose levels, so this also doubles as the first continuous glucose monitor. Between 1978 and 1988, Robert Channon, working with Guy's Hospital and the Bristol Royal Infirmary, developed a series of miniature insulin infusion pumps. Today, insulin pumps are so small that they can fit in a pocket or a purse. In the late 1970s and early 1980s, Sandia National Laboratories and the University of New Mexico School of Medicine developed a remotely programmable implantable insulin infusion system that was tested in animals and implanted in human patients beginning in 1981. In 1984, an Infusaid implantable infusion device was used to treat a 22-year-old patient successfully. The insulin pump was first endorsed in the United Kingdom in 2003 by the National Institute for Health and Care Excellence (NICE).
The ease with which our potatoes lend themselves to all sorts of stews gave me the idea of composing a meal of them, to which I invited several amateurs; and at the risk of being thought to be afflicted with potato mania, I will end this review by describing it: it was a dinner. We were first served two soups, one of mashed potatoes from our roots, the other of a fatty broth, in which the potato bread simmered quite well without crumbling; then came a matelote followed by a dish in white sauce, then another in maitre d'hôtel, and finally a fifth in roux. The second service consisted of five other dishes not less good than the first; first a pâté, a frying, a salad, fritters, and the economic cake of which I gave the recipe; the remainder of the meal was not very extensive, but delicate and good; a cheese, a pot of jam, a plate of cookie, another of tarts, and finally a brioche also of potatoes, made up the dessert; after that we had the coffee, also described above. There were two kinds of bread; the one mixed with potato pulp and wheat flour, fairly represented soft bread; the second, made of potato pulp, with their starch, bore the name of firm dough bread; I would have wished that fermentation had put me in a position to make a drink of our roots, to fully satisfy my guests, and to say with foundation: "Do you like potatoes, we have put them everywhere." Every one was cheerful; and if potatoes are drowsy, they produce on us a very opposite effect.
== Early life == Tracy Lauren Marrow, the son of Solomon and Alice Marrow, was born in Newark, New Jersey on February 16, 1958. Solomon's family was originally from Virginia and Philadelphia, and Alice's family was originally from Louisiana. Both of his parents were African American. Ice-T states that his father was a "dark-skinned brother" while his mother was a "fair-skinned" black woman who looked like Dorothy Dandridge or Lena Horne. For decades, Solomon worked as a conveyor belt mechanic at the Rapistan Conveyor Company. When Marrow was a child, his family moved to upscale Summit, New Jersey. The first time race played a major part in Marrow's life was at the age of seven, when he became aware of the racism leveled by his white friends towards black children. Marrow surmised that he escaped similar treatment because they thought that he was white due to his lighter skin. Relaying this incident to his mother, she told him, "Honey, people are stupid"; her advice and this incident taught Marrow to control the way the negativity of others affected him. His mother died of a heart attack when he was in third grade. Solomon raised Marrow as a single father for four years, with help from a housekeeper. Marrow's first experience with illicit activity occurred after a bicycle that his father bought him for Christmas was stolen. After Marrow told his father, Solomon shrugged, "Well, then, you ain't got no bike".
=== Spring 2003 === A US veteran sergeant reports witnessing torture of journalists and writers all over Iraq. Kurdistan region was not an exception. Writers without Borders embarrassed the Iraqi government quite frequently in reports covering minority, women and marginalised Iraqis from all over the country but with much focus on Baghdad, Karkuk, Salahedin and Mosul. Honorably discharged US veteran, Sergeant Frank "Greg" Ford reports that he witnessed war crimes in Samarra, Iraq. According to Ford, several members of his own unit, the 205th Military Intelligence Brigade participated in the torture of Iraqi detainees as young as 14. Ather Karen al-Mowafakia died in Basra, while in British custody. Details about the investigation are not known. Gary Bartlam, a British soldier of the 7th Armoured Brigade, was arrested after submitting film to a photo developers shop in Tamworth, England while on leave. The photographs depict a gagged Iraqi POW suspended hanging by rope from a fork lift, and other pictures seem to show prisoners being forced to perform sexual acts. Bartlam and two other soldiers were convicted at court martial of abuse - a fourth soldier was cleared. British Lieutenant Colonel Tim Collins was alleged by US Army Major Re Biastre to have been responsible for mistreatment of Iraqi civilians and prisoners of war. Lieutenant Colonel Collins was later cleared of any wrongdoing by an MOD investigation.
== Functions of aquatic plants == One of the largest aquatic plants in the world is the Bolivian waterlily, which holds the Guinness World Record of having the largest undivided leaf at 3.2 m (10 ft 6 in) diameter; the smallest is the rootless duckweed, which is only 1 mm (0.039 in) across. Many small animals use aquatic plants such as duckweeds and lily pads for spawning or as protective shelters against predators both from above and below the water surface. Aquatic plants are important primary producers and are the basis of food web for many aquatic fauna, especially wetland species. They compete with phytoplanktons for excess nutrients such as nitrogen and phosphorus, thus reducing the prevalence of eutrophication and harmful algal blooms, and have a significant effect on riparian soil chemistry as their leaves, stems and roots slow down the water flow, capture sediments and trap pollutants. Excess sediment will settle into the stream bed due to the reduced flow rates, and some aquatic plants also have symbiotic microbes capable of nitrogen fixation and breaking down the pollutants trapped and/or absorbed by the roots. Historically, aquatic plants have been less studied than terrestrial plants, and management of aquatic vegetation has become an increasingly interested field as means to reduce agricultural pollution of water bodies.
Sources: en.wikipedia.org
== External links == Lesch-Nyhan Syndrome at NIH's Office of Rare Diseases GeneReview/NIH/UW entry on Lesch–Nyhan syndrome National Institute of Child Health and Human Development (NICHD) Love Never Sinks • Lesch Nyhan• Patient Advocacy Group
Diocletian reorganized the Roman army, in order to better counter the threat of the Germanic peoples of northern Europe as well as that of the Persians from the East. The army was formed by border and field units. The border (limitanei) units were to occupy the limes, the structured border fortifications, and were formed by professional soldiers with an inferior training. The field units were to stay well behind the border, and to move quickly where they were needed, with both offensive and defensive roles. Field units were formed by elite soldiers with high-level training and weapons. They were further divided into:
It has been suggested that snakes evolved the mechanisms necessary for venom formation and delivery sometime during the Miocene epoch. During the mid-Tertiary, most snakes were large ambush predators belonging to the superfamily Henophidia, which use constriction to kill their prey. As open grasslands replaced forested areas in parts of the world, some snake families evolved to become smaller and thus more agile. However, subduing and killing prey became more difficult for the smaller snakes, leading to the evolution of snake venom. The most likely hypothesis holds that venom glands evolved from specialized salivary glands. The venom itself evolved through the process of natural selection; it retained and emphasized the qualities that made it useful in killing or subduing prey. Today we can find various snake species in stages of this hypothesized development. There are the highly efficient envenoming machines - like the rattlesnakes - with large capacity venom storage, hollow fangs that swing into position immediately before the snake bites, and spare fangs ready to replace those damaged or lost. Other research on Toxicofera, a hypothetical clade thought to be ancestral to most living reptiles, suggests an earlier time frame for the evolution of snake venom, possibly to the order of tens of millions of years, during the Late Cretaceous. Snake venom is produced in modified parotid glands normally responsible for secreting saliva. It is stored in structures called alveoli behind the animal's eyes and ejected voluntarily through its hollow tubular fangs.
=== Down syndrome === Adults with Down syndrome had accumulation of amyloid in association with evidence of Alzheimer's disease, including declines in cognitive functioning, memory, fine motor movements, executive functioning, and visuospatial skills.
Sources: en.wikipedia.org
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.
The World Anti-Doping Agency classifies it as a prohibited peptide hormone. Athletes under anti-doping rules are not permitted to use it. Its presence can trigger a doping violation.
It is a fragment of growth hormone rather than a substance that signals the pituitary to release more hormone. Studies have not shown a consistent rise in IGF-1 or full growth hormone. Its metabolic effects, if any, appear separate from those of the complete hormone.
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.